Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the 38 th Annual J.P. Morgan Healthcare Con...
Gainers: ASLN +8.6% . NK +7.1% . SCS +5.5% . OBSV +2.8% . CTAS +2.8% . More news on: ASLAN Pharmaceuticals Limited, NantKwest, Inc., Steelcase Inc., Stocks on the move, , News on ETFs Read more ...
RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination w...
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2 nd Annual HealthCONx Con...
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with this Read more ...
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the Stifel Healthcare Conference. The pres...
G1 Therapeutics, Inc. (GTHX) Q3 2019 Earnings Conference Call November 05, 2019, 16:30 ET Company Participants Jeff Macdonald - Head, Investor & Public Relations Mark Velleca - CEO, President & Director Rajesh Malik - Chief Medical Officer and SVP, R&D Jennifer Mose...
Image source: The Motley Fool. G1 Therapeutics, Inc. (NASDAQ: GTHX) Q3 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading
G1 Therapeutics (NASDAQ: GTHX ): Q3 GAAP EPS of -$0.86 misses by $0.01 . More news on: G1 Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C., Nov....
News, Short Squeeze, Breakout and More Instantly...
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know: Accor...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...